Nektar Therapeutics (NKTR) Receivables - Net (2010 - 2025)

Nektar Therapeutics' Receivables - Net history runs 16 years deep, the most recent figure standing at $400000.0 for Q4 2025.

• On a quarterly basis, Receivables - Net changed N/A year-over-year to $400000.0 in Q4 2025; TTM through Dec 2025 was $400000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $400000.0, changed N/A from the prior year.
• Receivables - Net grew to $400000.0 in Q4 2025 per NKTR's latest filing, from $200000.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $30.2 million in Q1 2022 and bottomed at $200000.0 in Q3 2025.
• The 5-year median for Receivables - Net is $4.8 million (2022), against an average of $11.3 million.
• Across the five-year window, Receivables - Net tumbled 90.09% in 2023 and increased 20.77% in 2024, its largest moves.
• Year by year, Receivables - Net stood at $22.5 million in 2021, then plunged by 73.41% to $6.0 million in 2022, then tumbled by 79.85% to $1.2 million in 2023, then dropped by 0.75% to $1.2 million in 2024, then plunged by 66.56% to $400000.0 in 2025.
• Per Business Quant, the three latest NKTR Receivables - Net figures stand at $400000.0 (Q4 2025), $200000.0 (Q3 2025), and $1.2 million (Q2 2024).